



BlueRock Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 5, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel *Cell+Gene* platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock Therapeutics, will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 4:30 p.m. ET at the Boston Marriott Copley Place.

About BlueRock Therapeutics

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock's *Cell+Gene* platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock's culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.

###

Source: BlueRock Therapeutics, Inc.

Investors:

Candice Ellis, 978-879-7273

Associate Director, Investor Relations and Corporate Communications

cellis@bluerocktx.com

Media Contacts:

David Schull or Maggie Beller

Russo Partners, LLC

(646) 942-5631

Maggie.beller@russopartnersllc.com